BCLI vs. CSBR, OMGA, BLUE, ATHA, DBVT, ALVR, DTIL, IKNA, GRTS, and PLX
Should you be buying Brainstorm Cell Therapeutics stock or one of its competitors? The main competitors of Brainstorm Cell Therapeutics include Champions Oncology (CSBR), Omega Therapeutics (OMGA), bluebird bio (BLUE), Athira Pharma (ATHA), DBV Technologies (DBVT), AlloVir (ALVR), Precision BioSciences (DTIL), Ikena Oncology (IKNA), Gritstone bio (GRTS), and Protalix BioTherapeutics (PLX). These companies are all part of the "biological products, except diagnostic" industry.
Champions Oncology (NASDAQ:CSBR) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, community ranking, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.
Champions Oncology has higher revenue and earnings than Brainstorm Cell Therapeutics. Champions Oncology is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.
Champions Oncology has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.
In the previous week, Brainstorm Cell Therapeutics had 1 more articles in the media than Champions Oncology. MarketBeat recorded 1 mentions for Brainstorm Cell Therapeutics and 0 mentions for Champions Oncology. Brainstorm Cell Therapeutics' average media sentiment score of 1.04 beat Champions Oncology's score of 0.00 indicating that Champions Oncology is being referred to more favorably in the media.
41.3% of Champions Oncology shares are owned by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 45.7% of Champions Oncology shares are owned by company insiders. Comparatively, 5.5% of Brainstorm Cell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Champions Oncology currently has a consensus target price of $7.50, suggesting a potential upside of 63.04%. Given Brainstorm Cell Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Champions Oncology is more favorable than Brainstorm Cell Therapeutics.
Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Brainstorm Cell Therapeutics' net margin of -19.76%. Champions Oncology's return on equity of 0.00% beat Brainstorm Cell Therapeutics' return on equity.
Brainstorm Cell Therapeutics received 141 more outperform votes than Champions Oncology when rated by MarketBeat users. Likewise, 63.60% of users gave Brainstorm Cell Therapeutics an outperform vote while only 60.08% of users gave Champions Oncology an outperform vote.
Summary
Champions Oncology beats Brainstorm Cell Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Brainstorm Cell Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Brainstorm Cell Therapeutics Competitors List
Related Companies and Tools
